In this article
The Global Oncologist Network reported that a patient with advanced cardia cancer liver metastasis successfully survived for three years after treatment with a new technology in clinical trials, with his condition currently stable and life returned to normal. The patient was a 72-year-old male diagnosed with cardia cancer in January 2013, who underwent radical surgery to remove a 6×5×1 cm mass, with pathological detection confirming infiltrating ulcerative and poorly differentiated adenocarcinoma. After two courses of postoperative chemotherapy and Chinese medicine treatment, a CT review on July 26, 2013 revealed liver metastases of approximately 6×6 cm. Non-invasive treatment began on July 29, 2013.
The results over three years were remarkable. One month after treatment, the liver mass shrank significantly from 58.84 mm to 38.86 mm, with the patient's physical and mental condition improving noticeably. By six months, the mass had reduced to 29.09 mm, and after eight months to 24.48 mm. By May 26, 2016 — 35 months into treatment — the lesion had reduced to just 2 cm, with no other lesions found and the patient in good health.
This anti-cancer technology has received international recognition and has been introduced by many world-renowned cancer centers, with treatment data published at international oncology academic conferences. The technology combines a global medical accelerator with photochemotherapy, offering the advantages of both traditional radiation therapy and chemical drug therapy. It works through directional labeling and destruction of tumor cells via photochemical action, killing primary and metastatic tumors without harming normal tissue cells, while simultaneously stimulating the body to produce an immune response to greatly improve therapeutic effect. The treatment is safe, non-invasive, and precise, with low toxic side effects, making it suitable for almost all advanced cancers.
The Global Oncologist Network reminds patients with advanced cancer that while no treatment plan can completely cure cancer, the best outcomes are achieved through surgery as the primary approach, supplemented by radiotherapy and chemotherapy, combined with newer anti-cancer technologies — all under the principle of multi-disciplinary cooperation and individualized treatment tailored to each patient's specific condition.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Medical Disclaimer
This article is for educational purposes only and should not replace medical advice, diagnosis, or treatment from a qualified oncology specialist. Every patient's case is different. Treatment decisions should always be made after a review of complete medical records by the treating medical team.
Treatment availability, eligibility, timelines, and access can change. Any clinical trial participation depends on detailed review and approval by the trial hospital or investigator.